• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Activity of Pretomanid against Nontuberculous Mycobacteria.

作者信息

Zheng Huiwen, Wang Yiting, He Wencong, Li Feina, Xia Hui, Zhao Bing, Wang Shengfen, Shen Chen, Zhao Yanlin

机构信息

Laboratory of Respiratory Diseases, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Center for Children's Health, Beijing, China.

National Tuberculosis Reference Laboratory, Chinese Center for Disease Control and Prevention, Beijing, China.

出版信息

Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0181021. doi: 10.1128/AAC.01810-21. Epub 2021 Nov 1.

DOI:10.1128/AAC.01810-21
PMID:34723628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8765262/
Abstract
摘要

相似文献

1
Activity of Pretomanid against Nontuberculous Mycobacteria.普瑞曼尼对非结核分枝杆菌的活性。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0181021. doi: 10.1128/AAC.01810-21. Epub 2021 Nov 1.
2
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.贝达喹啉和德拉马尼对非结核分枝杆菌（包括大环内酯类耐药临床分离株）的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
3
A review of current and promising nontuberculous mycobacteria antibiotics.当前及有前景的非结核分枝杆菌抗生素综述。
Future Med Chem. 2021 Aug;13(16):1367-1395. doi: 10.4155/fmc-2021-0048. Epub 2021 Jun 24.
4
ECCMID 2018 meeting report: the continuing clinical challenge of nontuberculous mycobacteria lung disease.欧洲临床微生物学与传染病大会（ECCMID）2018年会议报告：非结核分枝杆菌肺病持续存在的临床挑战
Future Microbiol. 2018 Sep;13:1347-1349. doi: 10.2217/fmb-2018-0171. Epub 2018 Sep 26.
5
Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824).非靶向代谢组学揭示了普托马尼（PA-824）的一种新作用模式。
Sci Rep. 2018 Mar 23;8(1):5084. doi: 10.1038/s41598-018-23110-1.
6
Colorado mycobacteria conference 2022: Focus on Nontuberculous mycobacteria.2022年科罗拉多分枝杆菌会议：聚焦非结核分枝杆菌
Tuberculosis (Edinb). 2023 May;140:102338. doi: 10.1016/j.tube.2023.102338. Epub 2023 Mar 24.
7
Activity of Oxazolidinone Against Nontuberculous Mycobacteria in China.在中国恶唑烷酮对非结核分枝杆菌的活性
Microb Drug Resist. 2023 Mar;29(3):112-114. doi: 10.1089/mdr.2022.0216. Epub 2023 Jan 10.
8
Medications and monitoring in nontuberculous mycobacteria infections.非结核分枝杆菌感染的药物治疗与监测。
Clin Chest Med. 2015 Mar;36(1):55-66. doi: 10.1016/j.ccm.2014.11.001. Epub 2014 Dec 18.
9
Skin disease and nontuberculous atypical mycobacteria.皮肤病与非结核性非典型分枝杆菌
Int J Dermatol. 2000 Sep;39(9):659-66. doi: 10.1046/j.1365-4362.2000.00821.x.
10
Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.非结核分枝杆菌的抗分枝杆菌药物敏感性测试。
J Clin Microbiol. 2019 Sep 24;57(10). doi: 10.1128/JCM.00834-19. Print 2019 Oct.

引用本文的文献

1
Genomic-based genotype and drug susceptibility profile of in China.中国基于基因组的基因型和药物敏感性概况。
Front Microbiol. 2025 Apr 29;16:1573448. doi: 10.3389/fmicb.2025.1573448. eCollection 2025.
2
Reinvigorating AMR resilience: leveraging CRISPR-Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security-a systematic review.重振抗菌药物耐药性的恢复力：利用CRISPR-Cas技术潜力对抗2024年世界卫生组织细菌重点病原体以加强全球卫生安全——一项系统综述
Trop Med Health. 2025 Apr 2;53(1):43. doi: 10.1186/s41182-025-00728-2.
3
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.结核病和非结核分枝杆菌肺部疾病的治疗进展。
Nat Rev Drug Discov. 2024 May;23(5):381-403. doi: 10.1038/s41573-024-00897-5. Epub 2024 Feb 28.
4
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.治疗非结核分枝杆菌感染的药物：来自意大利传染病和热带医学学会分枝杆菌研究组的叙述性综述。
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
5
Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.利用可再利用药物和天然产物中的潜在先导化合物来应对非结核分枝杆菌。
Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.
6
Epidemiology of Nontuberculous Mycobacteria in Nanjing and Mutations Associated with Clofazimine Resistance in .南京非结核分枝杆菌的流行病学及与氯法齐明耐药相关的突变
Infect Drug Resist. 2023 May 6;16:2751-2764. doi: 10.2147/IDR.S408986. eCollection 2023.
7
Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection.超越抗生素：非结核分枝杆菌感染诊断与管理的最新进展
Breathe (Sheff). 2022 Jun;18(2):210171. doi: 10.1183/20734735.0171-2021. Epub 2022 Jul 12.
8
Uncovering interactions between mycobacterial respiratory complexes to target drug-resistant .揭示分枝杆菌呼吸复合物之间的相互作用，以靶向耐药性。
Front Cell Infect Microbiol. 2022 Aug 24;12:980844. doi: 10.3389/fcimb.2022.980844. eCollection 2022.

本文引用的文献

1
Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, including Macrolide-/Amikacin-Resistant Clinical Isolates.利福霉素衍生物对非结核分枝杆菌的活性，包括对大环内酯类/阿米卡星耐药的临床分离株
Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.02611-20. Epub 2021 Mar 8.
2
Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from .分枝杆菌对PA-824的体外敏感性比较，以鉴定来自……的依赖脱氮黄素的硝基还原酶Ddn的关键残基。
Infect Drug Resist. 2020 Mar 11;13:815-822. doi: 10.2147/IDR.S240716. eCollection 2020.
3
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.贝达喹啉和德拉马尼对非结核分枝杆菌（包括大环内酯类耐药临床分离株）的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
4
Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China.贝达喹啉和德拉马尼对中国北京分离的非结核分枝杆菌的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00031-19. Print 2019 Aug.
5
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.含贝达喹啉治疗方案治疗耐多药和广泛耐药结核病的高治疗成功率。
Eur Respir J. 2018 Dec 20;52(6). doi: 10.1183/13993003.01528-2018. Print 2018 Dec.
6
Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.贝达喹啉和德拉马尼治疗耐多药结核病：韩国多中心队列研究。
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.02467-2017. Print 2018 Mar.
7
Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.替加环素对非结核分枝杆菌的药敏试验
J Clin Microbiol. 2017 Jun;55(6):1747-1754. doi: 10.1128/JCM.00274-17. Epub 2017 Mar 22.